• Home
  • Contact Us
  • Français
  • About Us
    • Vision
    • Who We Are
    • Why Choose King
    • Strategy
    • Fast Facts
  • |
  • Products
    • EpiPen.ca
    • Cytomel
  • |
  • Newsroom
    • FAQs
  • |
  • Business Development

News

It’s Life and Death: Canadian Actress Speaks Out About Living with Severe Allergies

EpiPen® Partners with Lucy Waverman, Canadian Culinary Personality,
to Offer Fresh, Natural Recipes for People Who Suffer from Life-Threatening Allergies

New Study Shows Most Canadians Not Prepared for Potentially Fatal Allergic Reactions

Montréal Broadcaster Normand Brathwaite Advises Quebeckers to Prepare for Allergy Season

King Pharmaceuticals Canada Launches EpiPen® Expiration Reminder

King Pharmaceuticals Acquires Exclusive Rights to EpiPen® in Canada

EpiPen® (epinephrine) Auto-Injector

Therapeutic Area: Acute Care

This product is distributed by:

  • King Pharmaceuticals Canada Inc. (Canada)

Full Prescribing Information - French (pdf 272 KB) Full Prescribing Information - English (pdf 271 KB)

For more information about EpiPen® Auto-Injectors, please visit www.EpiPen.ca

EpiPen® and EpiPen® Jr are registered trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Dey Pharma, L.P. of Basking Ridge, New Jersey, USA.

Get Adobe Reader
  • Home
  • About Us
  • Products
  • Newsroom
  • Business Development
  • Contact Us
  • Site Map
  • Legal
  • King Pharmaceuticals, Inc.

©2011 King Pharmaceuticals,® Inc. All rights reserved.

 

King Pharmaceuticals is now part of Pfizer Inc. The integration of King and Pfizer entities may be pending in various local jurisdictions and integration may be subject to completion of various local legal and regulatory obligations. All content in this message is subject to works council and/or union consultations, if applicable, and other legal requirements where appropriate.